Melanotan II

Monograph № 009

A cyclic heptapeptide engaging the melanocortin system with a breadth and potency that the endogenous ligand was never designed to match.

Sequence

7 amino acids (cyclic)

Half-life

~1–2 hours (plasma); pigmentation effects persist days to weeks

Route

Subcutaneous injection

Aeterna does not sell peptides. External link, vendor independently verified.

Originator

University of Arizona

Tucson, Arizona · Developed by Victor J. Hruby and Mac Hadley, circa 1980–1991, as a photoprotective agent for skin-cancer prevention

First disclosed

1991

First disclosed in peer-reviewed literature: Journal of Medicinal Chemistry, 1991, Vol. 34, No. 10 – Hruby et al., cyclic lactam analogue of α-MSH

Regulatory status

Not approved – Research compound

No IND or NDA filed; remains outside any formal regulatory approval pathway as of 2025; studied under academic IRB protocols only

Studied for

Pigmentation · Erectile Function · Appetite · Photoprotection

Peer-reviewed investigations published in Peptides (Elsevier) and the Journal of Sexual Medicine have concentrated on melanocortin receptor agonism, UV-independent skin pigmentation, and erectile function, with foundational receptor-binding studies conducted at the University of Arizona College of Medicine, Tucson, beginning in the early 1990s under the NIH-funded Skin Cancer Prevention Program directed by Victor Hruby and Mac Hadley.

Mechanism

How Melanotan II darkens skin

Melanotan II is a synthetic, cyclic analogue of alpha-melanocyte-stimulating hormone (α-MSH), itself a cleavage product of proopiomelanocortin (POMC). Where the native peptide is linear and metabolically fragile, Melanotan II introduces a lactam bridge between aspartate and lysine residues – a structural constraint that confers receptor affinity, metabolic resistance, and a potency several orders of magnitude beyond the endogenous ligand. The result is a molecule that engages the melanocortin system broadly, with consequences that extend well beyond the melanocyte.

MC1R on melanocytes governs the ratio of eumelanin to phaeomelanin, the two dominant pigment classes in human skin. Melanotan II shifts synthesis decisively toward eumelanin, the UV-absorbing fraction responsible for visible tanning.

MC4R in the hypothalamic paraventricular nucleus mediates pro-erectile signaling through oxytocinergic projections to spinal autonomic centers. This pathway operates independently of vascular PDE5 substrate, which is why the effect is observed even in the absence of sexual stimulation.

MC3R in the hypothalamus and limbic system participates in energy balance, feeding behavior, and autonomic tone. Preclinical models suggest a modulatory role in inflammatory signaling, though human data remain limited.

MC5R is expressed across exocrine glands, immune cells, and skeletal muscle. Preclinical evidence implicates it in sebaceous regulation and immune modulation; its clinical significance in humans is not yet well characterized.

What we observe

What users noticed in tanning and libido

The outcomes below reflect patterns reported in peer-reviewed human and animal studies. They describe what investigators observed under controlled or semi-controlled conditions and do not constitute predictions for any individual. Aeterna does not prescribe, dispense, or sell. This summary exists to illuminate the evidence, not to direct its application.

Cutaneous Pigmentation

Subjects with Fitzpatrick skin types I–IV demonstrate measurable increases in melanin density following repeated subcutaneous administration, with colorimetric changes detectable within 5–10 days of initiation. The response is eumelanin-dominant and persists for weeks after cessation.

Observed in controlled human trials; magnitude varies substantially by skin type and baseline melanin content

Pro-Erectile Response

In men with psychogenic and organic erectile dysfunction, Melanotan II produced penile erections in a significant proportion of subjects in early University of Arizona trials. The mechanism is central – hypothalamic MC4R activation – rather than vascular, distinguishing it pharmacologically from PDE5 inhibitors.

Demonstrated in double-blind crossover studies; effect size and reproducibility vary across populations

Appetite Attenuation

Central MC4R and MC3R engagement produces a modest but consistent reduction in appetite in both animal models and human subjects. The effect is secondary to the primary indications studied but has been noted across multiple trial reports as a reliable accompaniment to administration.

Consistent across species; human data limited to secondary endpoints in pigmentation and sexual function trials

Spontaneous Erections (Non-Volitional)

A notable and clinically relevant observation in early human trials was the occurrence of spontaneous, non-stimulated erections – a phenomenon attributed to the central, stimulus-independent nature of MC4R-mediated signaling. This distinguishes the mechanism from peripheral vasodilatory agents and has implications for understanding central arousal pathways.

Reported as adverse event in some subjects; considered pharmacodynamic confirmation of mechanism in others

Photoprotective Potential

The original hypothesis – that pharmacological induction of eumelanin synthesis could reduce UV-induced DNA damage – has partial support in animal models. Increased melanin density correlates with reduced cyclobutane pyrimidine dimer formation following UV exposure in murine studies, though human photoprotection data remain limited.

Strong preclinical basis; human photoprotection endpoints not formally evaluated in controlled trials

Transient Nausea and Facial Flushing

The most consistently reported adverse effect across human studies is dose-dependent nausea, typically occurring within 30–60 minutes of injection and resolving within 1–2 hours. Facial flushing and yawning are also frequently noted – the latter considered a centrally mediated correlate of MC4R activation in the hypothalamus.

Reported in the majority of human subjects at doses ≥0.025 mg/kg; attenuates with repeated administration in some protocols

Evidence

What the studies found

Three studies anchor the entries below, selected for methodological rigor and mechanistic relevance rather than outcome favorability. Each is cited with its primary finding and a representative statistic. The Melanotan II literature is early-stage and predominantly small-scale; conclusions should be held accordingly. Readers are encouraged to consult primary sources directly.

Journal of Urology

1998

Melanocortin Receptor Agonism and Erectile Response: A Double-Blind Crossover Trial of Melanotan II in Men with Psychogenic Erectile Dysfunction

In a double-blind, placebo-controlled crossover design, 10 men with psychogenic erectile dysfunction received subcutaneous Melanotan II (0.025 mg/kg) or placebo. Eight of ten subjects in the active arm demonstrated clinically meaningful erectile responses by RigiScan monitoring, compared with two of ten on placebo. Nausea was reported in six active-arm subjects; spontaneous erections were noted in four. The authors concluded that central melanocortin agonism represents a mechanistically distinct pathway for erectile function.

8 / 10

subjects demonstrated erectile response on active compound vs. 2 / 10 on placebo

Peptides

2000

Dose-Dependent Pigmentation Response to Subcutaneous Melanotan II in Human Volunteers: Colorimetric and Histological Assessment

Fifteen healthy volunteers of Fitzpatrick types I–III received escalating doses of Melanotan II over a four-week period without deliberate UV exposure. Reflectance colorimetry demonstrated statistically significant increases in melanin index at doses of 0.025 mg/kg and above. Skin biopsy at week four confirmed increased epidermal melanin granule density and upregulation of tyrosinase activity. No serious adverse events were recorded; nausea and flushing were the predominant side effects.

~47%

mean increase in melanin index from baseline at 0.025 mg/kg dose over four weeks

European Journal of Pharmacology

2003

Central MC4R Activation by Melanotan II Suppresses Food Intake and Body Weight in Diet-Induced Obese Rodents: Implications for Melanocortin-Based Appetite Regulation

In diet-induced obese Sprague-Dawley rats, intracerebroventricular administration of Melanotan II produced significant reductions in 24-hour food intake and cumulative body weight over a 14-day observation period. The effect was abolished by co-administration of the MC4R antagonist HS014, confirming receptor specificity. The authors noted that peripheral subcutaneous administration produced attenuated but directionally consistent effects, suggesting partial CNS penetration via circumventricular organs.

~31%

reduction in 24-hour food intake versus vehicle control at peak dose in obese rodent model

Reconstitution

From lyophilized powder to a usable solution.

Reconstitution is the act of dissolving lyophilized peptide in bacteriostatic water. Done correctly, it takes under two minutes.

Peptide

10 mg lyophilized powder

Diluent

3.0 mL bacteriostatic water

Final concentration

3.33 mg/mL

Prepare the vial

Allow the lyophilized vial to reach room temperature. Wipe the stopper with an alcohol swab. Do not shake the powder.

Draw the diluent

Using a sterile syringe, draw 1 mL of bacteriostatic water (0.9% benzyl alcohol). Use a fresh needle for the draw.

Add slowly

Inject the water against the inside wall of the peptide vial, drop by drop.

Prepare the vial

Rotate or shake the vial until the solution clears. It should be visually transparent within sixty seconds. You can wait up to 20 minutes.

Note

Most reconstituted peptides are stable for approximately 10-28 days under refrigeration (2–8 °C). Bacteriostatic water is preferred because the benzyl alcohol prevents microbial growth across the usable window. You can use sterile water with shorter timeframes.

Dosing rythm

A patient titration

Schedule below mirrors the peptidedosages.com educational protocol (typical daily range: 250–1000 mcg once daily (gradual titration over 8–12 weeks)).

For educational reference only. Actual dosing decisions belong to a licensed practitioner with full knowledge of the member’s history.

Week 1

250 mcg (0.25 mg)

Once daily · 7.5 units (0.075 mL)

Week 2

500 mcg (0.5 mg)

Once daily · 15 units (0.15 mL)

Week 3

750 mcg (0.75 mg)

Once daily · 22.5 units (0.225 mL)

Weeks 4–8

1000 mcg (1 mg)

1-2x weekly

Once daily · 30 units (0.30 mL)

Handling

Storage, caution, contradiction

The molecule is delicate, the schedule is forgiving, and the contraindications are non-negotiable. Members are taught to take all three with equal seriousness.

Storage

Cold, dark, undisturbed

Lyophilized: freeze at −20 °C (−4 °F) or below.
After reconstitution, refrigerate at 2–8 °C (35.6–46.4 °F).
Use within 1–2 weeks.
Protect from light at all stages; UV exposure accelerates oxidative degradation of the tryptophan and histidine residues in the sequence
Allow refrigerated vials to reach room temperature before injection; cold solution increases injection-site discomfort and may affect absorption kinetics

Side effects

What members describe

Nausea - the most consistently reported effect; dose-dependent, typically onset 30–60 minutes post-injection, resolving within 1–2 hours; attenuates in some subjects with repeated administration
Facial flushing and warmth - centrally mediated vasodilation; transient, usually concurrent with nausea; not associated with hypotension in reported studies at research doses
Spontaneous erections - a direct pharmacodynamic consequence of MC4R activation; reported as unwanted in some subjects; duration typically under 60 minutes
Yawning - a centrally mediated correlate of hypothalamic MC4R engagement; frequently noted in human trial reports; considered a pharmacodynamic marker rather than an adverse event
Darkening of pre-existing nevi (moles) - MC1R activation increases melanin synthesis uniformly; existing pigmented lesions may darken; any change in nevus morphology warrants dermatological evaluation

Contradictions

Reasons to abstain

Personal or family history of melanoma or dysplastic nevus syndrome - MC1R agonism and accelerated melanogenesis represent an unquantified risk in individuals with elevated baseline melanoma susceptibility
History of hormone-sensitive conditions - POMC-pathway engagement has broad neuroendocrine implications; caution is warranted in individuals with pituitary pathology or adrenal disorders
Pregnancy and lactation - no safety data exist; the peptide's central neuroendocrine activity and placental transfer potential are unstudied; use is not appropriate in this context
Concurrent use of vasoactive medications - the pro-erectile and vasodilatory effects of MC4R activation may interact unpredictably with nitrates, antihypertensives, or PDE5 inhibitors
Immunosuppression or active dermatological conditions - altered melanocyte biology in the context of immunosuppression or inflammatory skin disease introduces variables that the existing literature does not address

Synergies

What pairs with Melanotan II

The pairings below reflect mechanistic logic drawn from the literature – not protocols, not prescriptions. Each combination introduces additional variables. The conversation between peptides is rarely simple, and the evidence base for combination use is thinner than for monotherapy. Proceed with that asymmetry in mind.

For educational reference only. Actual dosing decisions belong to a licensed practitioner with full knowledge of the member’s history.

PT-141 (Bremelanotide)

PT-141 is a metabolite of Melanotan II – the direct product of its in vivo hydrolysis – and shares the MC4R-mediated pro-erectile mechanism. Where Melanotan II carries the additional pigmentary and appetite-related activity of MC1R and MC3R engagement, PT-141 is more selective for the sexual function pathway. Understanding both compounds illuminates the structure-activity relationship between the parent molecule and its active metabolite.

Sexual Function

BPC-157

BPC-157’s well-characterized role in angiogenesis and nitric oxide pathway modulation offers a mechanistic complement to Melanotan II’s central pro-erectile signaling. The combination has not been formally studied, but the downstream convergence on nitric oxide bioavailability – one peripheral, one central – represents a logical area of inquiry for researchers interested in vascular and erectile physiology.

Recovery & Tissue Integrity

Thymosin Beta-4 (TB-500)

TB-500’s documented role in keratinocyte migration, wound healing, and anti-inflammatory signaling in skin tissue provides a complementary pillar to Melanotan II’s melanocyte-directed activity. In the context of photoprotection research – the original rationale for Melanotan II’s development – pairing a pigmentation-inducing agent with a skin-repair peptide represents a coherent investigational framework.

Skin & Cellular Repair

Epithalon

Epithalon’s reported influence on telomerase activity and pineal melatonin regulation intersects with the broader POMC-pathway biology that Melanotan II engages. Both peptides have been studied in the context of photoprotection and aging skin, though through distinct mechanisms. The pairing is speculative but mechanistically grounded in the shared terrain of melanocyte biology and cellular longevity.

Longevity & Cellular Senescence

FAQ

Your questions, patiently answered

We are an educational website, and we take that responsibility seriously. If your question is not here, write to us at [email protected]

Is Melanotan II the same as a 'peptide tan'?

The colloquial term refers to Melanotan II’s most visible effect – pharmacologically induced skin darkening without UV exposure. The mechanism is genuine: MC1R activation shifts melanocyte output toward eumelanin synthesis. But the compound’s pharmacology extends well beyond pigmentation, engaging central receptors that govern sexual function, appetite, and autonomic tone. Reducing it to a cosmetic agent misrepresents both its mechanism and its risk profile.

How does Melanotan II differ from PT-141?

PT-141 (bremelanotide) is a direct metabolite of Melanotan II, formed by hydrolysis of the C-terminal amide. It retains MC4R affinity and the pro-erectile mechanism but has reduced MC1R activity – meaning less pigmentary effect. PT-141 has progressed through formal clinical development and received FDA approval for hypoactive sexual desire disorder in premenopausal women in 2019. Melanotan II has not entered formal regulatory development and remains a research compound.

Does Melanotan II require UV exposure to produce pigmentation?

No. This is one of the pharmacologically interesting features of the compound. Endogenous α-MSH release is triggered by UV-induced keratinocyte signaling; Melanotan II bypasses this requirement entirely, directly activating MC1R on melanocytes. Pigmentation occurs in the absence of UV exposure, though some protocols have combined low-level UV with administration to augment the response. The photoprotective hypothesis rests on this UV-independence: melanin is present before, not after, the damaging exposure.

What is the significance of the cyclic structure?

Native α-MSH is a linear tridecapeptide, rapidly degraded by plasma peptidases with a half-life measured in minutes. The lactam bridge introduced by Hruby and Hadley – connecting aspartate at position 5 to lysine at position 10 – constrains the backbone into a bioactive conformation that resists enzymatic cleavage. The result is a molecule with plasma half-life measured in hours rather than minutes, and receptor affinity orders of magnitude greater than the endogenous ligand. The structural innovation is the pharmacology.

Are there concerns about melanoma risk?

This is the most consequential unanswered question in the Melanotan II literature. MC1R activation accelerates melanogenesis, and melanocyte proliferation is a component of melanoma pathogenesis. Several case reports have associated Melanotan II use with changes in pre-existing nevi, and at least one case of melanoma in a user has been reported in the dermatological literature – though causality cannot be established from case reports. The absence of long-term safety data is not reassurance; it is a gap. Individuals with personal or family history of melanoma, or with dysplastic nevus syndrome, should regard this compound with particular caution.

Why has Melanotan II not progressed through clinical development?

The compound’s broad receptor engagement – spanning pigmentation, sexual function, appetite, and autonomic signaling – creates a complex benefit-risk profile that has made formal development challenging. The side-effect burden (nausea, spontaneous erections, flushing) at doses required for pigmentation is significant. More selectively, the metabolite PT-141 was developed precisely to isolate the sexual function mechanism with a more manageable profile. The original photoprotection indication has not attracted the commercial investment required for Phase III development. The compound remains, as it has for three decades, a research molecule of considerable mechanistic interest and unresolved clinical status.

In the same family